logo
Turtles could hold key to curing cancer

Turtles could hold key to curing cancer

Yahoo10-07-2025
Turtles could hold the key to finding a cure for cancer, researchers have found.
Creatures that are both large and long-lived typically face a higher risk of getting the disease, but turtles seem to defy that pattern.
The reason may lie in their strong defence against cell damage, slow metabolism, which reduces cellular stress, and unique genes that protect against cancer, researchers said.
In the study, scientists from the universities of Nottingham and Birmingham analysed medical records of autopsies from hundreds of zoo turtles, including some from Chester Zoo in Cheshire.
They found that 1 per cent had been affected by cancer, far less than in mammals or birds. It also discovered that, when tumours did appear, they almost never spread.
Some turtle species – which included tortoises – have life spans beyond 100. The Galapagos and Aldabra giant tortoises, for example, have lived beyond 150. In April, a female of the species became a first-time mother at the age of 100 in Philadelphia Zoo.
Credit: Philadelphia Zoo Digital
The researchers said the findings highlighted how essential it was to protect endangered species.
Dr Ylenia Chiari, one of the authors of the study from the school of life sciences at the University of Nottingham, said: 'Turtles, especially iconic species like Galapagos and Aldabra giant tortoises, are famous for living long lives and growing to tremendous sizes.
'You'd expect that to mean more cancer, but our study, which combines decades of zoo records with previous research, shows how incredibly rare cancer is in these animals.
'It highlights turtles as an untapped model for understanding cancer resistance and healthy ageing, and it shows the vital role zoos play in advancing science through collaboration.'
Dr Scott Glaberman, from the University of Birmingham, added: 'Biodiversity has so much to teach us about how the world works.
'While fascinating in their own right, extreme species like giant tortoises may have already solved many of the problems humans face, including those related to ageing and cancer. That makes biodiversity doubly worthy of protection.'
Dr Helena Turner, the research officer at Chester Zoo, said: 'It's fantastic to see these efforts not only contribute to advancing scientific knowledge around cancer resistance but also support vital conservation work to protect these remarkable species that may hold keys to medical breakthroughs benefiting both wildlife and humans.'
The study was published in the journal BioScience.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

Yahoo

time23 minutes ago

  • Yahoo

Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

Yahoo

timean hour ago

  • Yahoo

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

BROOMFIELD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ('Aclarion' or the 'Company') (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that scan volume has achieved significant year over year growth of 132% from 2Q24 to 2Q25 and has demonstrated two consecutive quarters of growth for the first time. Scan volume growth is a key catalyst for driving revenue and securing favorable payments from insurance companies. Given the steady cadence of new physician adoption, the activation of new commercial sites in the U.S., CLARITY study sites completing the onboarding process, and the approval from three of the top four private insurance payers in the UK to cover Nociscan, the Company believes it is on a steady trajectory to deliver consistent quarter over quarter scan volume growth through the remainder of 2025 and beyond. Aclarion is pursuing two core key catalysts to drive value. The first is scan volume growth in the UK where the obstacle of not having approval from insurers to pay for Nociscan has been removed. Over 5.2 million people in the UK now have access to Nociscan through their insurance provider. This market serves as a bellwether for all future markets where reimbursement precedes broad physician adoption. The Company is pursuing an aggressive strategy in this market to drive awareness and adoption, first through our partners at The London Clinic, and then throughout the London market. In an encouraging sign, early results in the UK are driving the majority of Nociscan volume increases the Company is currently reporting and management expects to see this accelerate. 'The first half of 2025 was marked by significant scan volume growth as we continue to gain commercial traction and build upon the clinical and economic evidence through real-world studies and the CLARITY trial,' states Brent Ness, CEO, Aclarion. 'Seeing the volume grow in London following the positive coverage example of Axa, Vitality and Aviva in the UK market with our customer, The London Clinic, validates our strategy and fuels our confidence that the payer community will move to encourage use of Nociscan leading to consistent revenue growth.' The second key catalyst the Company is focused on to drive value is the CLARITY trial, as results of this trial are expected to be a critical drive to securing widespread insurance coverage in the United States. The Company believes CLARITY represents the first ever prospective randomized trial to link a non-invasive AI (augmented intelligence) algorithm to better surgical outcomes for patients with low back pain. With chronic low back pain being part of the highest cost diagnosis in the U.S., and clinical results from surgical intervention showing an average success rate of only 54% across the literature, the importance of additional information for surgeons to better match their surgical plan to the pain their patient is experiencing is critical. Nociscan provides this information by objectively measuring the biomarkers in each disc that have been demonstrated to correlate with pain. CLARITY is designed to prove that when a surgeon uses Nociscan in conjunction with their current surgical planning process, they achieve successful surgical outcomes for chronic low back pain that far exceed the industry average of 54%. The Company has now engaged eight Phase I sites with four sites fully onboarded and activated: Texas Back Institute, University of Miami Health, Advocate Health, and Northwestern Medicine. The remaining 4 Phase I sites are expected to be activated by end of year. The Texas Back Institute enrolled the first patient in June and the Company is on track to fully enroll all 300 patients by Q4 2026. As the CLARITY trial progresses, the Company will be conducting an internal analysis of three month clinical outcomes to get a preliminary look at how impactful Nociscan is in driving better early clinical outcomes. Although the formal CLARITY protocol calls for evaluating outcomes at the standard one and two year follow up milestones, management believes three month outcomes will provide highly predictive information about the ultimate formal results of the trial. The Company expects to have visibility into a meaningful number of three month patients in the second quarter of 2026. This information is expected to be a significant milestone and key catalyst for the Company. Additional 2025 key milestones and highlights include: EVIDENCE and PUBLICATIONS. A core component of driving payment coverage for Nociscan is building clinical evidence and more specifically, getting this evidence published in peer-reviewed journals. In 2Q25, Clinicoeconomics and Outcomes Research published an independent cost-effectiveness analysis of Nociscan, led by a renowned healthcare economist from UCSF. The analysis concluded that Nociscan is more effective and less costly than provocative discography, illustrating that Nociscan saves $1,712 per patient and improves surgical success rates by 10%. In addition to the cost-effectiveness analysis, Aclarion continues to invest in the development of real-world evidence with customers in the UK and US. Finally, in 4Q24, Siemens Healthineers published a featured Nociscan Case Study on their global website, MAGNETOM WORLD. Siemens Healthineers is a global market share leader in medical imaging, in-vitro diagnostics, and advanced therapies. CUSTOMERS. In the absence of Category I coverage by private health insurance companies in the U.S., and Aclarion's focus on driving scan volume in the UK, the Company remains very selective with regards to adding new customers outside of the UK. Three strategic U.S. customers were added in the first half of 2025, including Scripps Health in San Diego and the Spine Institute of Louisiana, both of whom are prioritizing development of real-world evidence. Additionally Medical Imaging Center of Southern California expanded Nociscan access to a second location in Santa Monica. Aclarion will continue to add customer sites in markets with strategic relevance and customers committed to excellence in spine care. CONFERENCES. A key component to securing payment for Nociscan in the U.S. is demonstrating the support of surgeons and securing the backing of key spine societies. Participating in professional conferences is a leading strategy to establish relevance and credibility amongst surgeons and their societies. In 1H25, Aclarion participated in six important industry conferences where use of MR Spectroscopy was discussed as a distinct innovation in low back pain. Nociscan specifically was presented by leading spine surgeons at three different conferences: the 28th Annual Selby Spine Conference, the 2025 Spine Summit, and the 20th Annual State of Spine Surgery Think Tank. The Company will continue to participate in key industry conferences in 2H25 including Bridging the Gap, the International Society of Pain & Neuroscience (ISPN) conference in London, Sonntag Spine Symposium, the NASS 40th Annual Meeting, The Radiological Society of North America, and the Minimally Invasive Spine Society. INTELLECTUAL PROPERY. In February, Aclarion secured its 24th US patent to protect expanded applications of Magnetic Resonance Spectroscopy (MRS) data processing to identify pain and infection biomarkers throughout the body. Currently Aclarion holds 24 US-issued patents, 13 European issued patents, as well as several pending patent applications. The Company is in the process of auditing its intellectual property portfolio to evaluate spinning off additional companies in partnership with private investors to optimize the value of the patent portfolio for shareholders without increasing burn. FUNDING. At the end of 1Q25, Aclarion announced a funding update that included raising nearly $15M (net) cash on hand, as well as eliminating all debt, no preferred equity, and no warrants with strike prices near the current market. These funding activities helped to ensure that Aclarion is fully NASDAQ compliant and funded to execute on the strategic objectives highlighted in company communications and outlined in this update. The Company reaffirms it is adequately funded through Q3 2026 to prove out the key catalysts of demonstrating significant scan volume growth in the UK and securing early visibility into the success of CLARITY. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes. For more information about CLARITY, please visit: CLARITY Trial To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@ About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. Smith PCG Advisory, Inc. ksmith@ Media Contacts: Jennie Kim SPRIG Consulting jennie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ketamine's Antidepressant Action May Depend on Opioid System
Ketamine's Antidepressant Action May Depend on Opioid System

Medscape

time3 hours ago

  • Medscape

Ketamine's Antidepressant Action May Depend on Opioid System

Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store